The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection

Hongzhi Liu,1,2,* Hui Chen,1,* Xiaomo Wu,3,4 Ying Sun,2 Yingchao Wang,2 Yongyi Zeng,1,2 Geng Chen,2 Xiaolong Liu,2 Xiaohua Xing,2,5 Bixing Zhao,2 Jingfeng Liu1,21Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350007, People’s Rep...

Full description

Bibliographic Details
Main Authors: Liu H, Chen H, Wu X, Sun Y, Wang Y, Zeng Y, Chen G, Liu X, Xing X, Zhao B, Liu J
Format: Article
Language:English
Published: Dove Medical Press 2019-04-01
Series:Cancer Management and Research
Subjects:
Online Access:https://www.dovepress.com/the-serum-proteomics-tracking-of-hepatocellular-carcinoma-early-recurr-peer-reviewed-article-CMAR
id doaj-6a8004e9b25b4436904c00113d7724ba
record_format Article
spelling doaj-6a8004e9b25b4436904c00113d7724ba2020-11-25T00:01:43ZengDove Medical PressCancer Management and Research1179-13222019-04-01Volume 112935294645024The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resectionLiu HChen HWu XSun YWang YZeng YChen GLiu XXing XZhao BLiu JHongzhi Liu,1,2,* Hui Chen,1,* Xiaomo Wu,3,4 Ying Sun,2 Yingchao Wang,2 Yongyi Zeng,1,2 Geng Chen,2 Xiaolong Liu,2 Xiaohua Xing,2,5 Bixing Zhao,2 Jingfeng Liu1,21Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350007, People’s Republic of China; 2The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China; 3Department of Biomedicine, University of Basel, Basel 4056, Switzerland; 4Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Fuzhou 350025, People’s Republic of China; 5The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, People’s Republic of China  *These authors contributed equally to this work Purpose: There is still lacking of highly sensitive and specific biomarkers for the prediction of hepatocellular carcinoma (HCC) early recurrence, which has hindered further improvement of the clinical outcomes. We aim to find highly sensitive and specific biomarkers for the prediction of HCC recurrence.Patients and methods: By using isobaric tags for relative and absolute quantitation (iTRAQ)-based multidimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) technique, we have quantitatively investigated and monitored the proteome alterations of a series of serum after radical resection during the follow-up of 4 HCC patients.Results: A total of 27 differentially abundant proteins (DAPs) in serum were identified to be closely associated with the early recurrence of HCC, and these DAPs were particularly concentrated within ERK1/2 and nuclear factor-κ beta signaling pathways, suggesting the dysregulation of these two pathways played an important role in the pathological process of HCC early recurrence. Further investigation of a cohort of patients confirmed that the high serum level of PGK1 was closely associated with HCC early recurrence and poor prognosis. In addition, the serum level of PGK1 could be complementary with AFP to further improve the sensitivity and specificity for predicting the relapse of HCC.Conclusion: PGK1 might be an independent factor for the recurrence of HCC. And the PGK1 could be complementary with AFP to further improve the sensitivity and specificity in prognostic prediction of HCC relapse.Keywords: hepatocellular carcinoma, early recurrence, serum proteomics, iTRAQ, PGK1https://www.dovepress.com/the-serum-proteomics-tracking-of-hepatocellular-carcinoma-early-recurr-peer-reviewed-article-CMARHepatocellular carcinomaearly recurrenceserum proteomicsiTRAQPGK1
collection DOAJ
language English
format Article
sources DOAJ
author Liu H
Chen H
Wu X
Sun Y
Wang Y
Zeng Y
Chen G
Liu X
Xing X
Zhao B
Liu J
spellingShingle Liu H
Chen H
Wu X
Sun Y
Wang Y
Zeng Y
Chen G
Liu X
Xing X
Zhao B
Liu J
The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
Cancer Management and Research
Hepatocellular carcinoma
early recurrence
serum proteomics
iTRAQ
PGK1
author_facet Liu H
Chen H
Wu X
Sun Y
Wang Y
Zeng Y
Chen G
Liu X
Xing X
Zhao B
Liu J
author_sort Liu H
title The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
title_short The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
title_full The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
title_fullStr The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
title_full_unstemmed The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
title_sort serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
publisher Dove Medical Press
series Cancer Management and Research
issn 1179-1322
publishDate 2019-04-01
description Hongzhi Liu,1,2,* Hui Chen,1,* Xiaomo Wu,3,4 Ying Sun,2 Yingchao Wang,2 Yongyi Zeng,1,2 Geng Chen,2 Xiaolong Liu,2 Xiaohua Xing,2,5 Bixing Zhao,2 Jingfeng Liu1,21Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350007, People’s Republic of China; 2The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China; 3Department of Biomedicine, University of Basel, Basel 4056, Switzerland; 4Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Fuzhou 350025, People’s Republic of China; 5The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, People’s Republic of China  *These authors contributed equally to this work Purpose: There is still lacking of highly sensitive and specific biomarkers for the prediction of hepatocellular carcinoma (HCC) early recurrence, which has hindered further improvement of the clinical outcomes. We aim to find highly sensitive and specific biomarkers for the prediction of HCC recurrence.Patients and methods: By using isobaric tags for relative and absolute quantitation (iTRAQ)-based multidimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) technique, we have quantitatively investigated and monitored the proteome alterations of a series of serum after radical resection during the follow-up of 4 HCC patients.Results: A total of 27 differentially abundant proteins (DAPs) in serum were identified to be closely associated with the early recurrence of HCC, and these DAPs were particularly concentrated within ERK1/2 and nuclear factor-κ beta signaling pathways, suggesting the dysregulation of these two pathways played an important role in the pathological process of HCC early recurrence. Further investigation of a cohort of patients confirmed that the high serum level of PGK1 was closely associated with HCC early recurrence and poor prognosis. In addition, the serum level of PGK1 could be complementary with AFP to further improve the sensitivity and specificity for predicting the relapse of HCC.Conclusion: PGK1 might be an independent factor for the recurrence of HCC. And the PGK1 could be complementary with AFP to further improve the sensitivity and specificity in prognostic prediction of HCC relapse.Keywords: hepatocellular carcinoma, early recurrence, serum proteomics, iTRAQ, PGK1
topic Hepatocellular carcinoma
early recurrence
serum proteomics
iTRAQ
PGK1
url https://www.dovepress.com/the-serum-proteomics-tracking-of-hepatocellular-carcinoma-early-recurr-peer-reviewed-article-CMAR
work_keys_str_mv AT liuh theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT chenh theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT wux theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT suny theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT wangy theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT zengy theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT cheng theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT liux theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT xingx theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT zhaob theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT liuj theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT liuh serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT chenh serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT wux serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT suny serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT wangy serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT zengy serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT cheng serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT liux serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT xingx serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT zhaob serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
AT liuj serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection
_version_ 1725440803438854144